HF 862 Minnesota House · 2025-2026 Regular Session

Public postsecondary institutions required to maintain a supply of opiate antagonists on system campuses.

HF 862 requires all public Minnesota colleges and universities (including the University of Minnesota and Minnesota State Colleges) to maintain a supply of naloxone (an opiate antagonist used to reverse overdoses) on every campus building. Specifically, institutions must have at least two doses of nasal naloxone available onsite at each building and follow established protocols for storage and administration. The bill also directs the state health commissioner to provide training resources, including videos, to help campuses implement these emergency response measures. This requirement takes effect for the 2025-2026 academic year. The bill does not change who can administer naloxone but ensures campuses are prepared to respond to opioid overdoses.
Bill status in committee 1 of 4 stages cleared
Introduction
Feb 2025
Committee Review
Floor Vote
Governor
Introduced Feb 17, 2025 Last action Mar 27, 2025
Maddy AI version diff · 1 comparison

What changed between versions

Introduction 1st Engrossment · 1 edit · Mar 17, 2025
MINOR
The bill has moved from its initial introduction to its first engrossment, indicating it has been reviewed and amended by the legislature. The most significant substantive change is a broadening of the requirement for schools to stock naloxone; it now mandates having at least two doses of a nasal opiate antagonist at each campus residential building, rather than just any campus building. This change expands the scope of the requirement to specifically target residential areas on campus, likely to better address overdose risks in housing settings.
Scope change
The bill's scope regarding naloxone availability was narrowed from all campus buildings to specifically 'campus residential buildings'.
REQUIREMENT

The requirement for schools to stock naloxone was changed from 'each campus building' to 'each campus residential building', and the specific drug was generalized from 'nasal naloxone' to 'nasal opiate antagonist'.

Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
5
Key actions
1
Committee
1
Mar 17, 2025
Lower · Passed
Committee report, to adopt as amended and re-refer to Health Finance and Policy
lower
Feb 17, 2025
Introduced
Introduction and first reading, referred to Higher Education Finance and Policy
lower
1 primary · 5 co-sponsors

Sponsors